Physician profile
Matthew Ulrickson
NPI 1790980316
$25,104.88
in general payments reported to CMS, 2019-2025
15 companies · $516 in 2025
The $516 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2021: $1,985 · 2022: $5,360 · 2023: $8,043 · 2024: $9,004 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $1,699 · Travel and Lodging: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,071.00 |
| Food and Beverage | $1,699.15 |
| Travel and Lodging | $791.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $8,560.12 | 2022-2024 | |
| Genentech, INC. | $5,577.39 | 2023 | Venclexta |
| Stemline Therapeutics INC. | $2,925.00 | 2022 | |
| Abbvie INC. | $2,362.33 | 2024 | |
| Genmab U.S., INC. | $2,255.09 | 2024 | Epkinly |
| Gilead Sciences, INC. | $1,930.00 | 2021 | |
| Celgene Corporation | $432.60 | 2021-2025 | Reblozyl, Onureg |
| Cti Biopharma Corp. | $306.54 | 2022 | |
| Adc Therapeutics America, INC. | $218.70 | 2023 | |
| Autolus INC | $175.29 | 2025 | |
| Kite Pharma, INC. | $121.85 | 2025 | Yescarta |
| Novartis Pharmaceuticals Corporation | $103.05 | 2019 | |
| Verastem, INC. | $94.42 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $42.50 | 2023 | Epkinly |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ulrickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.